SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression

Katarzyna Mleczko-Sanecka1, Guillem Casanovas, Anan Ragab

  • 1Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany.

Blood
|December 31, 2009
PubMed

Insights

SMAD7 acts as a key suppressor of hepcidin, the hormone regulating iron metabolism. This discovery reveals a novel negative feedback pathway limiting hepcidin expression and preventing iron deficiency.

Area of Science:

  • Molecular biology
  • Iron metabolism
  • Signaling pathways

Background:

  • Hepcidin is the primary regulator of systemic iron metabolism, with deficiency causing iron overload and overexpression leading to anemia.
  • While BMP and JAK-STAT pathways activate hepcidin transcription, inhibitory mechanisms remain largely unknown.

Purpose of the Study:

  • To identify novel inhibitors of hepcidin expression.
  • To elucidate the regulatory mechanisms controlling hepcidin levels.

Main Methods:

  • High-throughput siRNA screening in primary murine hepatocytes.
  • Analysis of hepcidin promoter activity and SMAD protein interactions.

Main Results:

  • SMAD7 was identified as a potent suppressor of hepcidin transcription.
  • SMAD7 overexpression abrogated hepcidin activation by BMPs and TGF-β.
  • A distinct SMAD7-responsive motif (GTCAAGAC) in the hepcidin promoter was identified.

Conclusions:

  • SMAD7 represents a significant inhibitory factor for hepcidin expression.
  • A novel negative feedback loop involving SMAD7 in hepcidin regulation was uncovered.
  • This pathway provides insight into preventing iron deficiency by limiting hepcidin expression.

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...